Iparomlimab and Tuvonralimab in HNSCC

This study tests a new combination immunotherapy — iparomlimab plus tuvonralimab (two checkpoint inhibitor drugs that work on different immune pathways) — in people with recurrent or metastatic head and neck squamous cell carcinoma that has already progressed after two or more lines of treatment. **You may be eligible if...** - You are 18–75 years old - You have a confirmed diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (oropharynx, oral cavity, hypopharynx, or larynx) - Your cancer has progressed after 2 or more prior systemic treatments - You have adequate organ function and a good performance status (ECOG 0–1) - You have measurable disease **You may NOT be eligible if...** - You have not had prior systemic treatment for metastatic/recurrent disease - You have active autoimmune disease - You are pregnant or breastfeeding - You have uncontrolled infections or other cancers Talk to your doctor to see if this trial is right for you.